Related Experiment Videos
Stopping drug therapy in epilepsy
1Epilepsy Research Group, Institute of Neurology, University College London, UK. slhatoo@aol.com
Current Pharmaceutical Design
|June 1, 2000
Summary
Discontinuing antiepileptic drug (AED) therapy is complex due to fears of adverse events versus seizure recurrence risks. Improved understanding of epilepsy prognosis may simplify this decision for patients and doctors.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Initiating antiepileptic drug (AED) therapy is generally simpler than discontinuing it.
- Patients and physicians face a dilemma when considering AED withdrawal.
- Fear of long-term adverse events (e.g., vigabatrin, felbamate side effects) motivates discontinuation, while seizure recurrence risks deter it.
Purpose of the Study:
- To explore the complexities surrounding the decision to discontinue antiepileptic drug (AED) therapy.
- To highlight the factors influencing patient and physician decisions regarding AED withdrawal.
Main Methods:
- Review of clinical considerations in epilepsy management.
- Discussion of the balance between AED side effects and seizure relapse implications.
Main Results:
- The decision to stop AEDs is complicated by potential long-term adverse effects.
- Seizure recurrence poses significant risks including employment, driving, and social stigma.
- Limited understanding of epilepsy syndrome natural history hinders informed decisions on medication withdrawal.
Conclusions:
- A clearer understanding of epilepsy prognosis is needed to facilitate safer AED discontinuation.
- Predicting seizure relapse more accurately will reduce the challenges associated with stopping AEDs.
- Future advancements in epilepsy research may make medication withdrawal a less difficult process.